CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsHigh earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.03BCNY1.05B · vs all stocks (USD)
Trailing P/E
22.58xRevenue (TTM)
3.31BCNY494.70M · vs all stocks (USD)
Profit Margin
9.32%Beta
0.4110xvs all stocks
52-Week Change
-17.42%vs all stocks
Market Capitalization
7.03BCNY1.05B · vs all stocks (USD)
Enterprise Value
5.49BCNY819.87M · vs all stocks (USD)
Trailing P/E
22.58xForward P/E
11.39xPrice to Sales (TTM)
2.12xPrice to Book (MRQ)
1.42xEnterprise to Revenue
1.66xEnterprise to EBITDA
13.08xGross Margin
70.85%Profit Margin
9.32%Operating Margin
7.27%Return on Assets (TTM)
2.03%Return on Equity (TTM)
6.22%Revenue (TTM)
3.31BCNY494.70M · vs all stocks (USD)
Revenue per Share (TTM)
5.90CNYUpdated Sep 21, 2026Quarterly Revenue Growth
8.70%Gross Profit (TTM)
2.38BCNY355.37M · vs all stocks (USD)
EBITDA (TTM)
392.25MCNY58.57M · vs all stocks (USD)
Net Income (TTM)
308.72MCNY46.10M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.10%Operating Cash Flow (TTM)
548.34MCNY81.88M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-663.54MCNY-99.09M · vs all stocks (USD)
5-Year Average Dividend Yield
0.52%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
193.89MCNYFY2025 · Dec 31, 2025Revenue
3.29BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
940.31MCNYFY2025 · Dec 31, 2025Gross Profit
2.35BCNYFY2025 · Dec 31, 2025Operating Income
374.98MCNY56.00M · vs all stocks (USD)
Pre-tax Income
356.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
49.26MCNYFY2025 · Dec 31, 2025Net Income
307.30MCNYFY2025 · Dec 31, 2025EBIT
370.81MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
581.17MCNYFY2025 · Dec 31, 2025Research & Development
607.61MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.00BCNYFY2025 · Dec 31, 2025Other Operating Expenses
48.18MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
18.76MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
14.24MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
562.83MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
562.83MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
307.30MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-3.37MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
633.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
113.83MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.15BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
307.30MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.59MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
218.94MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
85.73MCNYFY2025 · Dec 31, 2025Capital Expenditures
-519.74MCNYFY2025 · Dec 31, 2025Purchase of Investments
-603.60MCNYFY2025 · Dec 31, 2025Sale of Investments
609.51MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-513.83MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-91.90MCNYFY2025 · Dec 31, 2025Other Financing Charges
-24.49MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-116.39MCNYFY2025 · Dec 31, 2025Shares Outstanding
566.16MSharesUpdated Sep 21, 2026Float Shares
335.13MSharesUpdated Sep 21, 2026% Held by Insiders
46.54%vs all stocks
% Held by Institutions
4.54%vs all stocks
Total Cash (MRQ)
1.96BCNY292.21M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.46CNYUpdated Sep 21, 2026Total Debt (MRQ)
413.03MCNY61.68M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0800xCurrent Ratio (MRQ)
1.92xBook Value per Share (MRQ)
8.77CNYUpdated Sep 21, 2026Total Assets
3.31BCNY494.75M · vs all stocks (USD)
Total Current Assets
3.31BCNYFY2025 · Dec 31, 2025Total Liabilities
1.85BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
129.03MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.72BCNYFY2025 · Dec 31, 2025Cash
2.11BCNYFY2025 · Dec 31, 2025Cash Equivalents
34.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.15BCNYFY2025 · Dec 31, 2025Accounts Receivable
464.94MCNYFY2025 · Dec 31, 2025Inventory
452.56MCNYFY2025 · Dec 31, 2025Accounts Payable
226.39MCNYFY2025 · Dec 31, 2025Short-term Debt
250.50KCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.97MCNYFY2025 · Dec 31, 2025Long-term Debt
805.34KCNYFY2025 · Dec 31, 2025Common Stock (Book)
566.16MCNYFY2025 · Dec 31, 2025Retained Earnings
4.22BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.01BCNY748.50M · vs all stocks (USD)
52-Week Low
10.69CNYUpdated Sep 21, 202652-Week High
16.61CNYUpdated Sep 21, 202652-Week Change
-17.42%vs all stocks
Beta
0.4110xvs all stocks
50-Day MA
12.60CNYUpdated Sep 21, 2026200-Day MA
13.41CNYUpdated Sep 21, 2026Avg 10-Day Volume
3.88MSharesUpdated Sep 21, 2026Avg 30-Day Volume
7.33MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.5500CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High earnings qualityNotable
Earnings Quality Score: 1.11
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zylox-Tonbridge Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MeiraGTx Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Ningbo United Group Co., Ltd.
1 interpretationClose Below 40W SMA With Profitability
Sinomach General Machinery Co., Ltd.
1 interpretationClose Below 40W SMA With Profitability
Shanghai Huayi Group Corp. Ltd.
1 interpretationClose Below 40W SMA With Profitability